DRI Healthcare Trust (TSE:DHT.UN) Receives C$21.83 Consensus Price Target from Analysts

DRI Healthcare Trust (TSE:DHT.UN) has received an average recommendation of “Buy” from the six analysts that are covering the company, Marketbeat.com reports. Five research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is C$21.83.

A number of research analysts recently issued reports on DHT.UN shares. National Bankshares lifted their price target on shares of DRI Healthcare Trust from C$22.00 to C$23.50 and gave the stock an “outperform” rating in a research note on Friday, March 1st. Scotiabank boosted their price objective on shares of DRI Healthcare Trust from C$22.00 to C$24.00 and gave the stock an “outperform” rating in a research report on Friday, February 2nd. CIBC boosted their price objective on shares of DRI Healthcare Trust from C$19.00 to C$19.50 and gave the stock an “outperform” rating in a research report on Friday, March 1st. Raymond James upgraded shares of DRI Healthcare Trust from an “outperform” rating to a “strong-buy” rating and boosted their price objective for the stock from C$22.00 to C$24.00 in a research report on Friday, March 1st. Finally, Stifel Nicolaus boosted their price objective on shares of DRI Healthcare Trust from C$21.00 to C$22.00 and gave the stock a “buy” rating in a research report on Friday, March 1st.

DRI Healthcare Trust Price Performance

Shares of DRI Healthcare Trust stock opened at C$11.65 on Friday. DRI Healthcare Trust has a 52-week low of C$7.30 and a 52-week high of C$16.77. The business has a 50 day moving average price of C$14.85.

About DRI Healthcare Trust

DRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties. It owns a portfolio of 18 royalties derived from the sale of 14 various pharmaceutical products that focuses on eight therapeutic areas. The company was incorporated in 2020 and is headquartered in Toronto, Canada.